Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis.
The purpose of this study was to analyze the effect of the soluble TNF-alpha receptor etanercept on the serum levels of IL-16, IL-17, IL-23, and macrophage inflammatory protein-3alpha (MIP-3alpha) in rheumatoid arthritis (RA) patients. Twenty-two patients with RA were administered etanercept once or twice a week for more than 6 months, and we evaluated clinical and laboratory parameters and serum levels of IL-16, IL-17, IL-23, and MIP-3alpha at the baseline and at 3 and 6 months. Additionally, the production of IL-23 and MIP-3alpha of cultured synovial cells stimulated with TNF-alpha from RA patients was determined by ELISA. We also used ELISA kits to determine synovial fluid (SF) levels of IL-17, IL-23, and MIP-3alpha in patients with RA, osteoarthritis (OA), pseudogouty arthritis (PGA), and gouty arthritis (GA). A significant decrease in serum levels of IL-23 and MIP-3alpha was observed at 3 and 6 months after initial treatment of etanercept. TNF-alpha induced MIP-3alpha but not IL-23 production in cultured synovial cells from RA patients. SF levels of IL-17, IL-23, and MIP-3alpha in RA patients showed significantly higher levels than those of OA, PGA, and GA patients. This study demonstrated that the reduction of IL-23 and MIP-3alpha production in RA patients was a newly determined function of etanercept.
Kageyama
Yasunori
Y
Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. Tsukatonpipi@nifty.com
Ichikawa
Tetsuya
T
Nagafusa
Tetsuyuki
T
Torikai
Eiji
E
Shimazu
Masahiro
M
Nagano
Akira
A
D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015210:Arthritis, Gouty / Q000097:blood / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D002478:Cells, Cultured; D054418:Chemokine CCL20 / Q000097:blood*; D000068800:Etanercept; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D019410:Interleukin-16 / Q000097:blood; D020381:Interleukin-17 / Q000097:blood; D053759:Interleukin-23 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D013582:Synovial Fluid / Q000737:chemistry / Q000187:drug effects; D013583:Synovial Membrane / Q000737:chemistry / Q000166:cytology / Q000187:drug effects
D018501:Antirheumatic Agents; D015415:Biomarkers; D054418:Chemokine CCL20; D007074:Immunoglobulin G; D019410:Interleukin-16; D020381:Interleukin-17; D053759:Interleukin-23; D018124:Receptors, Tumor Necrosis Factor; D002097:C-Reactive Protein; D000068800:Etanercept